Arch Biopartners Receives Permission From U.S. FDA to Proceed With Phase II Acute Kidney Injury Trial
June 27, 2023 07:15 ET
|
Arch Biopartners
Approval from FDA to initiate Phase II trial with LSALT peptide to target cardiac surgery-associated acute kidney injury (CS-AKI)LSALT peptide targets dipeptidase-1 (DPEP-1), an enzyme known to...
Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials
August 05, 2022 07:30 ET
|
Arch Biopartners
TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company targeting acute organ inflammation with...
Arch Biopartners Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase II Trial for LSALT Peptide
February 02, 2021 07:56 ET
|
Arch Biopartners
TORONTO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval in Turkey from the İstanbul...
Arch Biopartners Closes Non-Brokered Private Placement
December 29, 2020 08:33 ET
|
Arch Biopartners
TORONTO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Arch Biopartners Arranges Non-Brokered Private Placement
December 23, 2020 08:53 ET
|
Arch Biopartners
TORONTO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
Arch Biopartners Receives Government of Canada Funding to Support Phase II Therapeutic Trial of Metablok for COVID-19
December 15, 2020 12:52 ET
|
Arch Biopartners
Government of Canada contribution up to $6.7 MillionFunding from the department of Innovation, Science and Economic Development through the Strategic Innovation Fund and part of the Government of...
VA San Diego Healthcare System Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients
December 10, 2020 07:27 ET
|
Arch Biopartners
TORONTO, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Veterans Affairs San Diego Healthcare System...
Arch Biopartners Announces Dosing of First Patient in Turkey in Phase II Trial of LSALT peptide to Treat Complications from Covid-19
November 05, 2020 08:04 ET
|
Arch Biopartners
TORONTO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient dosing in Turkey has begun in the Phase...
Arch Biopartners Receives Approval from Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide; Begins Screening Patients in Florida
October 07, 2020 07:58 ET
|
Arch Biopartners
TORONTO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval in Turkey from the Ministry...
Arch Biopartners Receives Ethics Committee Approval in Turkey for Phase II Trial for LSALT Peptide
September 10, 2020 08:59 ET
|
Arch Biopartners
TORONTO, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it received approval in Turkey from the...